Affiliation:
1. From the Departments of Biochemistry, Cancer Biology, and Internal Medicine, Wake Forest University School of Medicine and the Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC; the Radiation Oncology Branch, National Institutes of Health, Bethesda, MD; and the Department of Chemistry, University of New Hampshire, Durham, NH.
Abstract
AbstractWe have synthesized a novel six-coordinate metal chelator from the triamine cis-1,3,5-triaminocyclohexane by the addition of a 2-pyridylmethyl pendant arm on each nitrogen, which we term tachpyr. The experiments described here were designed to explore whether this compound exhibits potential antitumor activity. When added to MBT2 or T24 cultured bladder cancer cells, tachpyr was profoundly cytotoxic, with an IC50 of approximately 4.6 μmol/L compared with 70 μmol/L for desferioxamine. To explore the mode of action of tachpyr, several metal complexes were prepared, including Fe(II), Ca(II), Mn(II), Mg(II), Cu(II), and Zn(II) tachpyr complexes. Of these, the Zn(II), Cu(II), and Fe(II) complexes were without toxic effect, whereas the Ca(II), Mn(II), and Mg(II) complexes remained cytotoxic. To further probe the role of Zn(II) and Cu(II) chelation in the cytotoxicity of tachpyr, sterically hindered tachpyr derivatives were prepared through N-alkylation of tachpyr. These derivatives were unable to strongly bind Fe(III) or Fe(II) but were able to bind Zn(II) and Cu(II). When added to cells, these sterically hindered tachpyr derivatives were nontoxic, consistent with a role of iron depletion in the cytotoxic mechanism of tachpyr. Further, the addition of tachpyr to proliferating cultures resulted in an early and selective inhibition of ferritin synthesis, an iron storage protein whose translation is critically dependent on intracellular iron pools. Taken together, these experiments suggest that tachpyr is a cytotoxic metal chelator that targets intracellular iron, and that the use of tachpyr in cancer therapy deserves further exploration.© 1998 by The American Society of Hematology.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference30 articles.
1. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.;Kemp;Cancer Res,1995
2. Direct evidence that iron deprivation induces apoptosis in murine lymphoma.;Kovar;Pathobiology,1997
3. Role of deferoxamine in tumor therapy.;Donfrancesco;Acta Haematol,1996
4. Dose escalation of desferrioxamine (DFO) in children with refractory neuroblastoma: A Pediatric Oncology Group study.;Frantz;Proc Am Soc Clin Oncol,1994
5. Chemotherapy of advanced transitional-cell carcinoma of the bladder.;Miller;Cancer Chemother Pharmacol,1992
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献